Article

FDA approves Lenstec IOL

The FDA has approved a new IOL (Softec HD, Lenstec) for patients with cataracts.

St. Petersburg, FL

-The FDA has approved a new IOL (Softec HD, Lenstec) for patients with cataracts.

The lens already is in use throughout the European Union, Australia, Canada, China, and other international markets. More than 1 million of the IOLs have been implanted worldwide since 2005, according to its maker, which also maintains that the IOL is manufactured with a tolerance of 0.125 D.

“Lens variability is one of the leading causes of refractive error for patients who undergo cataract surgery,” said Jim Simms, Lenstec vice president.

The company’s technology reduces variability and enables surgeons to target each patient's prescription better, he added.

In addition to reducing variability, the company’s manufacturing process makes it possible to produce the lenses in 0.25-D increments for prescriptions from +18 to +25 D, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
© 2025 MJH Life Sciences

All rights reserved.